Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.

Sikov, William M; Dizon, Don S; Strenger, Rochelle; Legare, Robert D; Theall, Kathy P; Graves, Theresa A; Gass, Jennifer S; Kennedy, Teresa A; Fenton, Mary Anne

Sikov, William M; Dizon, Don S; Strenger, Rochelle; Legare, Robert D; Theall, Kathy P; Graves, Theresa A; Gass, Jennifer S; Kennedy, Teresa A; Fenton, Mary Anne.

Affiliation

Sikov WM; Department of Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02906, USA. wsikov@lifespan.org

J Clin Oncol ; 27(28): 4693-700, 2009 Oct 01.

Article in En | MEDLINE | ID: mdl-19720916

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: J Clin Oncol Year: 2009 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google